394 related articles for article (PubMed ID: 19667717)
1. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
2. Changes in physicians' practice of prescribing cyclooxygenase-2 inhibitor after market withdrawal of rofecoxib: a retrospective study of physician-patient pairs in Taiwan.
Hsiao FY; Tsai YW; Huang WF
Clin Ther; 2009 Nov; 31(11):2618-27. PubMed ID: 20110006
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Wong M; Chowienczyk P; Kirkham B
Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
[TBL] [Abstract][Full Text] [Related]
4. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
5. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
[TBL] [Abstract][Full Text] [Related]
6. [COX-2 inhibitors--one step forward and two steps back].
Evensen S; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2005 Apr; 125(7):875-8. PubMed ID: 15815733
[TBL] [Abstract][Full Text] [Related]
7. COX-2 inhibitors--lessons in drug safety.
Psaty BM; Furberg CD
N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
[No Abstract] [Full Text] [Related]
8. [Cardiovascular risks of Cox-2-antagonists. Opinion on the marketed name rofecoxib, and its market-withdrawn valdecoxib and the actual therapeutic restrictions].
Bolten WW; Reiter S;
Z Rheumatol; 2005 May; 64(4):286-9. PubMed ID: 15909092
[No Abstract] [Full Text] [Related]
9. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib.
Bäck M; Yin L; Ingelsson E
Eur Heart J; 2012 Aug; 33(15):1928-33. PubMed ID: 22108833
[TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
11. Cardiovascular effects of cyclooxygenase-2 inhibitors.
Brophy JM
Curr Opin Gastroenterol; 2007 Nov; 23(6):617-24. PubMed ID: 17906437
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.
Schug SA; Joshi GP; Camu F; Pan S; Cheung R
Anesth Analg; 2009 Jan; 108(1):299-307. PubMed ID: 19095866
[TBL] [Abstract][Full Text] [Related]
13. COX-2 inhibitors and heart.
Manoria P; Manoria PC
Indian Heart J; 2005; 57(6):772-7. PubMed ID: 16521658
[No Abstract] [Full Text] [Related]
14. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
15. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
[TBL] [Abstract][Full Text] [Related]
16. COX-2 inhibitors and the heart: are all coxibs the same?
Sooriakumaran P
Postgrad Med J; 2006 Apr; 82(966):242-5. PubMed ID: 16597810
[TBL] [Abstract][Full Text] [Related]
17. Adverse cardiovascular effects of rofecoxib.
Furberg CD
N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442
[No Abstract] [Full Text] [Related]
18. Cox-2 inhibitors: still no decisive action.
Prescrire Int; 2005 Jun; 14(77):102. PubMed ID: 15981408
[TBL] [Abstract][Full Text] [Related]
19. Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.
Klasser GD; Epstein J
J Can Dent Assoc; 2005 Sep; 71(8):575-80. PubMed ID: 16202197
[TBL] [Abstract][Full Text] [Related]
20. COX-2 selective inhibitors cardiac toxicity: getting to the heart of the matter.
Davies NM; Jamali F
J Pharm Pharm Sci; 2004 Oct; 7(3):332-6. PubMed ID: 15576013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
